Edition:
United States

Emergent BioSolutions Inc (EBS.N)

EBS.N on New York Stock Exchange

28.57USD
21 Apr 2017
Change (% chg)

$-0.53 (-1.82%)
Prev Close
$29.10
Open
$29.00
Day's High
$29.13
Day's Low
$28.55
Volume
60,682
Avg. Vol
124,382
52-wk High
$44.29
52-wk Low
$24.48

EBS.N

Chart for EBS.N

About

Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical... (more)

Overall

Beta: 1.13
Market Cap(Mil.): $1,170.12
Shares Outstanding(Mil.): 40.96
Dividend: --
Yield (%): --

Financials

  EBS.N Industry Sector
P/E (TTM): 21.07 57.54 29.95
EPS (TTM): 1.36 -- --
ROI: 6.94 -0.41 13.21
ROE: 9.95 6.21 14.38

BRIEF-Emergent Biosolutions signs $53 mln modification to Barda contract for manufacture of botulism antitoxin

* Emergent Biosolutions signs $53 million modification to Barda contract for the manufacture of botulism antitoxin

Mar 31 2017

BRIEF-Emergent Biosolutions awarded $100 mln BARDA contract

* Emergent Biosolutions awarded $100 million BARDA contract for Biothrax deliveries to the strategic national stockpile

Mar 17 2017

BRIEF-Emergent Biosolutions reports Q4 EPS $0.67

* Fy2017 earnings per share view $2.08, revenue view $543.1 million -- Thomson Reuters I/B/E/S

Feb 23 2017

BRIEF-Emergent BioSolutions receives German Federal Ministry of Health Approval of Building 55 for large-scale manufacturing of BioThrax

* Emergent BioSolutions receives German Federal Ministry of Health Approval of Building 55 for large-scale manufacturing of BioThrax

Jan 27 2017

BRIEF-Aptevo Therapeutics receives $20 mln payment from Emergent Biosolutions

* Aptevo Therapeutics receives $20 million payment from Emergent Biosolutions

Jan 13 2017

BRIEF-Emergent Biosolutions announces preliminary 2016 financial results

* Emergent Biosolutions announces preliminary 2016 financial results and provides 2017 financial outlook

Jan 09 2017

BRIEF-Emergent Biosolutions Q3 adjusted EPS $0.58 from continuing operations

* Emergent biosolutions reports third quarter and nine months 2016 financial results

Nov 07 2016

More From Around the Web

Competitors

Earnings vs. Estimates